Accueil / Tag Archives: Contract/Agreement

Tag Archives: Contract/Agreement

Granules India to Add 102 Jobs, Invest $35 Million in Fairfax County Pharmaceutical R&D, Manufacturing Operation

Monday, May 22nd 2017 at 2:30pm UTC Hyderabad-based company expanding presence in Chantilly area FAIRFAX COUNTY, Va.–(BUSINESS WIRE)– Governor Terry McAuliffe today announced that Granules India Ltd., a vertically integrated pharmaceutical company, will invest $35 million into its wholly owned subsidiary, Granules Pharmaceuticals Inc., to expand its pharmaceutical R&D and …

Plus »

ICON and Regeneron Win Best Partnership in Clinical Research Award from PharmaTimes

Wednesday, May 24th 2017 at 9:00am UTC ICON & Regeneron recognised for demonstrating successful collaboration between pharma & CRO DUBLIN–(BUSINESS WIRE)– ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and Regeneron Pharmaceuticals, Inc., a leading science-based biopharmaceutical …

Plus »

Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

Tuesday, May 23rd 2017 at 8:01pm UTC Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen’s focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.–(BUSINESS WIRE)– Debiopharm International SA (Debiopharm – www.debiopharm.com), part of Debiopharm Group™, a Switzerland-based …

Plus »

Clinical Ink and endpoint Announce Industry-First Alliance

Tuesday, May 23rd 2017 at 12:00pm UTC eSource and IRT Integration Simplifies the Site Experience SAN FRANCISCO & PHILADELPHIA–(BUSINESS WIRE)– endpoint Clinical, the leading global interactive response technology (IRT®) company, and Clinical Ink, the pioneering provider of eSource and patient engagement technologies, have teamed up to integrate IRT and eSource …

Plus »

Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals

Wednesday, May 24th 2017 at 2:00pm UTC LEXINGTON, Mass.–(BUSINESS WIRE)– Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that in connection with its annual shareholder meeting, Concert shareholders voted to approve the asset purchase agreement under which Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) will acquire CTP-656 and other assets related to the …

Plus »

FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications

Thursday, May 25th 2017 at 5:16pm UTC NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company’s proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent …

Plus »

bluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy

Tuesday, May 23rd 2017 at 12:00pm UTC – Collaboration includes industry leaders; aims to develop strategies for sustainable, value-based approach to access transformative gene therapy treatments – CAMBRIDGE, Mass.–(BUSINESS WIRE)– bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and …

Plus »

Carestream Health Receives New Innovative Technology Contract From Vizient, Inc., for Its OnSight 3D Extremity Imaging System

Tuesday, May 23rd 2017 at 12:30pm UTC ROCHESTER, N.Y.–(BUSINESS WIRE)– Carestream Health announced it has received an Innovative Technology contract from Vizient, Inc., for its CARESTREAM OnSight 3D Extremity System. Vizient is the largest member-driven health care performance improvement company in the country. The contract was based on a recommendation …

Plus »

Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau

Thursday, May 25th 2017 at 12:00pm UTC KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into an exclusive worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting …

Plus »

Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

Tuesday, May 23rd 2017 at 3:45pm UTC GENEVA & NANTES, France–(BUSINESS WIRE)– Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™. The …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE !
Vous appréciez cet article ? Faites-nous part de vos commentaires.
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cuZWVpLWJpb3RlY2hmaW5hbmNlcy5jb20vd3AtY29udGVudC91cGxvYWRzLzIwMTUvMDcvU2F0cmEtMi5tcDQiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...